|
Rep. Laura Faver Dias
Filed: 4/8/2025
| | 10400HB2346ham001 | | LRB104 06540 BDA 24827 a |
|
|
| 1 | | AMENDMENT TO HOUSE BILL 2346
|
| 2 | | AMENDMENT NO. ______. Amend House Bill 2346 by replacing |
| 3 | | everything after the enacting clause with the following: |
| 4 | | "Section 5. The Illinois Drug Reuse Opportunity Program |
| 5 | | Act is amended by changing Sections 5, 45, and 55 and by adding |
| 6 | | Section 70 as follows: |
| 7 | | (410 ILCS 715/5) |
| 8 | | Sec. 5. Definitions. In this Act: |
| 9 | | "Controlled substance" means a drug, substance, or |
| 10 | | immediate precursor in Schedules I through V of 21 CFR 1308. |
| 11 | | "Department" means the Illinois Department of Public |
| 12 | | Health. |
| 13 | | "Dispense" has the same meaning as defined in Section 3 of |
| 14 | | the Pharmacy Practice Act. |
| 15 | | "Donor" means any person, including an individual member |
| 16 | | of the public, or any entity legally authorized to possess |
|
| | 10400HB2346ham001 | - 2 - | LRB104 06540 BDA 24827 a |
|
|
| 1 | | medicine, including, but not limited to, a wholesaler or |
| 2 | | distributor, third party logistic provider, pharmacy, |
| 3 | | dispenser, clinic, surgical or health center, detention and |
| 4 | | rehabilitation center, jail, prison laboratory, medical or |
| 5 | | pharmacy school, prescriber or other health care professional, |
| 6 | | long-term care facility, or healthcare facility. "Donor" |
| 7 | | includes government agencies and entities that are federally |
| 8 | | authorized to possess medicine, including, but not limited to, |
| 9 | | drug manufacturers, repackagers, relabelers, outsourcing |
| 10 | | facilities, health care facilities operated by the U.S. |
| 11 | | Department of Veterans Affairs, and prisons. |
| 12 | | "Drug" means a prescription drug, over-the-counter drug, |
| 13 | | or supplies needed to administer a prescription or |
| 14 | | over-the-counter drug. |
| 15 | | "Eligible patient" means an individual: |
| 16 | | (1) with a prescription for the drug, if a |
| 17 | | prescription is required to dispense the drug, or who |
| 18 | | reports symptoms treated by the drug if the drug is |
| 19 | | over-the-counter; and |
| 20 | | (2) who is registered with the drug's manufacturer in |
| 21 | | accordance with federal Food and Drug Administration |
| 22 | | requirements, if the registration is required to dispense |
| 23 | | the drug. |
| 24 | | "Manufacturer" has the same meaning as defined in Section |
| 25 | | 15 of the Wholesale Drug Distribution Licensing Act. |
| 26 | | "Pharmacist" means an individual licensed to engage in the |
|
| | 10400HB2346ham001 | - 3 - | LRB104 06540 BDA 24827 a |
|
|
| 1 | | practice of pharmacy under the Pharmacy Practice Act or |
| 2 | | licensed to engage in the practice of pharmacy in another |
| 3 | | state. |
| 4 | | "Practitioner" means a person licensed in this State to |
| 5 | | dispense or administer drugs or who is licensed in another |
| 6 | | state as a person authorized to dispense or administer drugs. |
| 7 | | "Prescription drug" means any prescribed drug that may be |
| 8 | | legally dispensed by a pharmacy. "Prescription drug" does not |
| 9 | | include a drug for the treatment of cancer that can only be |
| 10 | | dispensed to a patient registered with the drug manufacturer |
| 11 | | in accordance with the federal Food and Drug Administration's |
| 12 | | requirements. |
| 13 | | "Priority patient" means an eligible patient who is an |
| 14 | | Illinois resident and who is indigent, uninsured, |
| 15 | | underinsured, or enrolled in a public health benefits program. |
| 16 | | "Recipient" means any person or entity legally authorized |
| 17 | | to possess medicine with a license or permit in the state in |
| 18 | | which the person or entity is located, including, but not |
| 19 | | limited to, a wholesaler or distributor, reverse distributor, |
| 20 | | repackager, hospital, pharmacy, or clinic. |
| 21 | | "Returns processor" has the same meaning as defined in |
| 22 | | paragraph (18) of 21 U.S.C. 360eee. "Returns processor" |
| 23 | | includes, but is not limited to, a reverse distributor. |
| 24 | | "Unopened tamper-evident packaging" has the same meaning |
| 25 | | as defined in the United States Pharmacopeia (USP) General |
| 26 | | Chapter 659, Packaging and Storage Requirements, including, |
|
| | 10400HB2346ham001 | - 4 - | LRB104 06540 BDA 24827 a |
|
|
| 1 | | but not limited to, unopened unit-dose, multiple-dose, |
| 2 | | immediate, secondary, and tertiary packaging. |
| 3 | | (Source: P.A. 102-389, eff. 1-1-22.) |
| 4 | | (410 ILCS 715/45) |
| 5 | | Sec. 45. Recordkeeping requirements. When performing any |
| 6 | | action associated with a program under this Act or otherwise |
| 7 | | processing a donated drug for tax, manufacturer, or other |
| 8 | | credit, a recipient shall be considered to be acting as a |
| 9 | | returns processor and shall comply with all recordkeeping |
| 10 | | requirements for nonsalable nonsaleable returns under federal |
| 11 | | law. Records maintained under this Act may be accessed by the |
| 12 | | Department upon request. |
| 13 | | (Source: P.A. 102-389, eff. 1-1-22.) |
| 14 | | (410 ILCS 715/55) |
| 15 | | Sec. 55. Retention of records. All records required under |
| 16 | | this Act shall be retained in physical or electronic format |
| 17 | | and on or off the recipient's premises for a period of 6 years. |
| 18 | | Donors or recipients may contract with one another or a third |
| 19 | | party to create or maintain records on each other's behalf. An |
| 20 | | identifier, such as a serial number or bar code, may be used in |
| 21 | | place of any or all information required by a record or label |
| 22 | | pursuant to this Act if it allows for such information to be |
| 23 | | readily retrievable. Upon request by a State or federal |
| 24 | | regulatory agency, the identifier used for requested records |
|
| | 10400HB2346ham001 | - 5 - | LRB104 06540 BDA 24827 a |
|
|
| 1 | | shall be replaced with the original information. An identifier |
| 2 | | shall not be used on patient labels when dispensing or |
| 3 | | administering a drug. Records maintained under this Act may be |
| 4 | | accessed by the Department upon request. |
| 5 | | (Source: P.A. 102-389, eff. 1-1-22.) |
| 6 | | (410 ILCS 715/70 new) |
| 7 | | Sec. 70. Program support provided by the Department. |
| 8 | | (a) The Department shall: |
| 9 | | (1) develop, maintain, and publish on its website |
| 10 | | information regarding the names and locations of |
| 11 | | pharmacies participating in the Illinois Drug Reuse |
| 12 | | Opportunity Program; |
| 13 | | (2) educate pharmacies in the State about the Illinois |
| 14 | | Drug Reuse Opportunity Program and how to participate in |
| 15 | | it voluntarily; |
| 16 | | (3) develop and publish educational materials to allow |
| 17 | | program participants and the Department to inform the |
| 18 | | general public about the purposes and benefits of the |
| 19 | | program; and |
| 20 | | (4) collect information from participants and publish |
| 21 | | the information in an annual report to the General |
| 22 | | Assembly by December 31 of each calendar year, beginning |
| 23 | | December 31, 2026. |
| 24 | | (b) Pharmacy participants are required to notify the |
| 25 | | Department of their participation in any program under this |